Literature DB >> 27418685

Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension.

Athanasios Charalampopoulos1, J Simon R Gibbs2, Rachel J Davies1, Wendy Gin-Sing1, Kevin Murphy3, Karen K Sheares4, Joanna Pepke-Zaba4, David P Jenkins5, Luke S Howard6.   

Abstract

We tested the hypothesis that patients with chronic thromboembolic pulmonary hypertension (CTEPH) that was deemed to be inoperable were more likely to respond to drugs for treating pulmonary arterial hypertension (PAH) by using cardiopulmonary exercise (CPX) testing than those with CTEPH that was deemed to be operable. We analyzed CPX testing data of all patients with CTEPH who were treated with PAH drugs and had undergone CPX testing before and after treatment at a single pulmonary hypertension center between February 2009 and March 2013. Suitability for pulmonary endarterectomy (PEA) was decided by experts in PEA who were associated with a treatment center. The group with inoperable CTEPH included 16 patients, the operable group included 26 patients. There were no differences in demographics and baseline hemodynamic data between the groups. Unlike patients in the operable group, after drug treatment patients with inoperable CTEPH had a significantly higher peak V̇o2 (P < 0.001), work load (P = 0.002), and oxygen pulse (P < 0.001). In terms of gas exchange, there was an overall net trend toward improved V̇e/V̇co2 in the group with inoperable CTEPH, with an increased PaCO2 (P = 0.01), suggesting reduced hyperventilation. No changes were observed in patients with operable CTEPH. In conclusion, treatment with PAH drug therapy reveals important pathophysiological differences between inoperable and operable CTEPH, with significant pulmonary vascular and cardiac responses in inoperable disease. Drug effects on exercise function observed in inoperable CTEPH cannot be translated to all forms of CTEPH.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  cardiopulmonary exercise testing; chronic thromboembolic pulmonary hypertension; pulmonary arterial hypertension drug therapy

Mesh:

Substances:

Year:  2016        PMID: 27418685      PMCID: PMC5142256          DOI: 10.1152/japplphysiol.00087.2016

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  19 in total

Review 1.  ATS/ACCP Statement on cardiopulmonary exercise testing.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2003-01-15       Impact factor: 21.405

2.  Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension.

Authors:  Jay Suntharalingam; Carmen M Treacy; Natalie J Doughty; Kimberley Goldsmith; Elaine Soon; Mark R Toshner; Karen K Sheares; Rodney Hughes; Nicholas W Morrell; Joanna Pepke-Zaba
Journal:  Chest       Date:  2008-02-08       Impact factor: 9.410

Review 3.  Chronic major-vessel thromboembolic pulmonary hypertension.

Authors:  K M Moser; W R Auger; P F Fedullo
Journal:  Circulation       Date:  1990-06       Impact factor: 29.690

4.  Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension.

Authors:  Marion Delcroix; Anton Vonk Noordegraaf; Elie Fadel; Irene Lang; Gérald Simonneau; Robert Naeije
Journal:  Eur Respir J       Date:  2012-08-16       Impact factor: 16.671

5.  Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  Zhenguo Zhai; Kevin Murphy; Hannah Tighe; Chen Wang; Martin R Wilkins; J Simon R Gibbs; Luke S Howard
Journal:  Chest       Date:  2011-04-28       Impact factor: 9.410

Review 6.  Chronic thromboembolic pulmonary hypertension.

Authors:  P Dartevelle; E Fadel; S Mussot; A Chapelier; P Hervé; M de Perrot; J Cerrina; F L Ladurie; D Lehouerou; M Humbert; O Sitbon; G Simonneau
Journal:  Eur Respir J       Date:  2004-04       Impact factor: 16.671

7.  Effects of nifedipine on ventilation/perfusion matching in primary pulmonary hypertension.

Authors:  C Mélot; R Naeije; P Mols; J L Vandenbossche; H Denolin
Journal:  Chest       Date:  1983-02       Impact factor: 9.410

8.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

Review 9.  Effect of pulmonary hypertension on gas exchange.

Authors:  A G Agustí; R Rodriguez-Roisin
Journal:  Eur Respir J       Date:  1993-10       Impact factor: 16.671

10.  Myoendothelial junctional complexes in postobstructive pulmonary vasculopathy: a quantitative electron microscopic study.

Authors:  R P Michel; F Hu; B O Meyrick
Journal:  Exp Lung Res       Date:  1995 May-Jun       Impact factor: 2.459

View more
  1 in total

1.  Diagnostic utility of sub-maximum cardiopulmonary exercise testing in the ambulatory setting for heart failure with preserved ejection fraction.

Authors:  Hannah T Oakland; Phillip Joseph; Ahmed Elassal; Marjorie Cullinan; Paul M Heerdt; Inderjit Singh
Journal:  Pulm Circ       Date:  2020-11-25       Impact factor: 3.017

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.